Swiss - Delayed Quote CHF

Novartis AG (NOVN.SW)

96.04

+0.74

+(0.78%)

At close: June 4 at 5:31:06 PM GMT+2

Novartis reports topline outcomes from trial of Pluvicto for prostate cancer

Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.

Clinical Trials Arena yesterday

NVS
ASCO25: Novartis hopes Scemblix becomes new standard for CML-CP

The ASC4FIRST study found Scemblix to be more effective than tyrosine kinase inhibitors.

Clinical Trials Arena 2 days ago

NVS
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 2 days ago

NVS
Zacks.com featured highlights Novartis, ENGIE, MasTec, Dorman Products and Sterling Infrastructure

NVS, ENGIY, MTZ, DORM, and STRL stand out as low-leverage stocks to help investors weather market volatility with confidence.

Zacks 2 days ago

NVS

ENGIY

DORM
Novartis' Pluvicto shown to slow prostate cancer in earlier setting

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a drug technology that the drugmaker has pioneered. The Swiss drugmaker reported a late-stage trial showed a "clinically meaningful benefit" in progression-free survival with a positive trend in overall survival in patients with metastatic prostate cancer that still responds to standard hormone therapy. Almost all of those patients ultimately progress to a form of cancer that no longer responds to hormone therapy, a setting where Pluvicto is already approved, the company added.

Reuters 2 days ago

NVS
Novartis’s Cancer Treatment Pluvicto Shows Positive Results in Trial

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

The Wall Street Journal 2 days ago

NVS

NVSEF
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS)1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting1,2Novartis to present results at an upcoming medical meetin

GlobeNewswire 2 days ago

NVS

NVSEF
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year post-treatment analysis1Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients1Rising breast cancer diagnosis rates and more aggressive disease in younger women underscore importance of early detection and care with effective and tolerable treatments that help prevent cancer recurrence2Sep

GlobeNewswire 3 days ago

NVS

NVSEF
Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment

NVS, ENGIY, MTZ, DORM and STRL offer low leverage and earnings growth, making them safer picks during periods of volatile market sentiment.

Zacks 5 days ago

NVS

ENGIY

DORM
What Makes Novartis AG (NVS) a Differentiated Business?

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund returned -3.35% compared to -1.32% for the MSCI ACWI Net Index. Stock selection in consumer staples, communication services, and healthcare sectors, and allocations to […]

Insider Monkey 8 days ago

NVS
Novartis announces commencement of tender offer to acquire Regulus Therapeutics

Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc., a Delaware corporation (“Regulus”), in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent

GlobeNewswire 8 days ago

NVS

NVSEF
Market Chatter: Court Denies Novartis' Motion to Dismiss Lawsuit Alleging Asthma Drug Caused Autism

A federal judge denied Novartis' (NVS) motion Tuesday to dismiss a lawsuit against the company broug

PREMIUM
MT Newswires 14 days ago

NVS
Are You Looking for a High-Growth Dividend Stock?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Zacks 14 days ago

NVS
Judge shuts down drugmakers’ 340B rebate plans, for now

A district court ruled that the HHS does have the power to review drug manufacturers’ plans to pay hospitals rebates instead of upfront discounts on 340B medications. But it left the door open to the controversial reforms.

Healthcare Dive 16 days ago

SNY

CELG-RT

NVS
Here's Why Novartis (NVS) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 19 days ago

NVS
Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?

Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 20 days ago

NVS
Should Value Investors Buy Novartis (NVS) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 20 days ago

NVS
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary endpoint results provide insights into use in earlier settingsFabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5Ianalumab Phase II data in immune thrombocytopenia and longer-term pelabresib Phase III data in myelofibrosis sho

GlobeNewswire 20 days ago

NVS

NVSEF
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.

Zacks 20 days ago

ITOS

NVS
RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US

Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.

Zacks 22 days ago

ROG.SW

LLY

NVS

Performance Overview

Return	NOVN.SW	MSCI WORLD (^990100-USD-STRD)
YTD	+12.15%	+4.87%
1-Year	+7.27%	+12.93%
3-Year	+32.57%	+40.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novartis AG (NOVN.SW)

Novartis reports topline outcomes from trial of Pluvicto for prostate cancer

ASCO25: Novartis hopes Scemblix becomes new standard for CML-CP

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks.com featured highlights Novartis, ENGIE, MasTec, Dorman Products and Sterling Infrastructure

Novartis' Pluvicto shown to slow prostate cancer in earlier setting

Novartis’s Cancer Treatment Pluvicto Shows Positive Results in Trial

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment

What Makes Novartis AG (NVS) a Differentiated Business?

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

Market Chatter: Court Denies Novartis' Motion to Dismiss Lawsuit Alleging Asthma Drug Caused Autism

Are You Looking for a High-Growth Dividend Stock?

Judge shuts down drugmakers’ 340B rebate plans, for now

Here's Why Novartis (NVS) is a Strong Value Stock

Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?

Should Value Investors Buy Novartis (NVS) Stock?

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US

Performance Overview